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Abstract The explosive global spreading of multidrug
resistant Mycobacterium tuberculosis (Mtb) has provoked
an urgent need to discover novel anti-TB agents. Enoyl-
acyl carrier protein reductase from Mtb is a well-known
and thoroughly studied target for anti-tuberculosis therapy.
In the present analysis, virtual screening techniques per-
formed from Drug bank database by utilizing INH-NAD
adduct as query for the discovery of potent anti-TB agents.
About 100 molecules sharing similar scaffold with INH-
NAD adduct were analyzed for their binding effectiveness.
The initial screening based on number of rotatable bonds
gave 42 hit molecules. Subsequently, physiochemical
properties such as toxicity, solubility, drug-likeness and
drug score were analyzed for the filtered set of compounds.
Final data reduction was performed by means of molecular
docking and normal mode docking analysis. The result
indicates that DB04362, adenosine diphosphate 5-(beta-
ethyl)-4-methyl-thiazole-2-carboxylic acid could be a
promising lead compound and be effective in treating
sensitive as well as drug-resistant strains of Mtb. We
believe that this novel scaffolds might be the good starting
point for lead compounds and certainly aid the experi-
mental designing of anti-tuberculosis drug in a short time.
Keywords INH-NAD adduct  Virtual screening 
Molecular docking  Bioavailability  Normal mode
analysis
Introduction
Tuberculosis (TB) is a chronic infectious disease caused by
mycobacteria such as Mycobacterium bovis, Mycobacte-
rium africanum and mainly Mycobacterium tuberculosis
(Aziz et al. 2006). One-third of the world’s population is
infected with Mycobacterium tuberculosis, the etiological
agent of TB, resulting in 9.2 million new cases and 1.7
million deaths in 2006 (Floyd and Pantoja 2008). Globally
in 2007, there were a predictable 13.7 million chronic
active cases. In 2010, there were 8.8 million new cases and
1.5 million associated deaths occurred in developing
countries. Active TB is usually treated with isoniazid
(INH) in association with one or more other anti-TB drugs
but multidrug-resistant TB (MDR-TB) and very recently
extensively drug-resistant TB (XDR-TB) have become a
serious and unsolved public health problem (Aziz et al.
2006; Pasqualoto et al. 2004; Wei et al. 2003; Morlock
et al. 2003; Ormerod 2005). INH is a prodrug and must be
activated by the catalase–peroxidase KatG (Zhang et al.
1992; Johnsson and Schultz 1994; Marcinkeviciene et al.
1995; Johnsson et al. 1997; Wang et al. 1998) and the
isoniazid-activated intermediate forms an isonicotinoyl-
NAD adduct (INH-NAD), through addition of either an
isonicotinic acyl anion to NAD? or an isonicotinic acyl
radical to an NAD radical (Rozwarski et al. 1998). After
activation, it inhibits enoyl-acyl carrier protein reductase
(InhA). Inhibition of this activity by INH blocks the bio-
synthesis of mycolic acids, which are major lipids of the
mycobacterial envelope (Quemard et al. 1996; Marrakchi
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et al. 2000). INH-NAD adduct is a slow tight binding
competitive inhibitor of InhA that binds with an overall
dissociation constant of 0.75 nM (Rawat et al. 2003).
Missense mutations in the inhA structural gene have been
identified in clinical isolates of Mycobacterium tuberculo-
sis resistant to INH. More studies have also demonstrated
that the mutations within katG in Mtb are common in INH-
resistant strains (Heym et al. 1995). The mutations within
inhA have been reported up to 32 % in INH resistant
strains (Telenti et al. 1997; Morris et al. 1995; Lee et al.
1999; Kiepiela et al. 2000). Mutations in katG and inhA
account for up to 80 % of INH-resistant strains (Morris
et al. 1995; Musser et al. 1996), whereas the mutations in
katG alone account for the majority of INH resistant strains
(Cynamon et al. 1999; Torres et al. 2000). This indicates
that high prevalence of resistance to INH was observed,
mainly due to emerging KatG mutants that do not activate
or poorly activate INH. Therefore, it has been suggested
that compounds that inhibit the ultimate target of INH but
do not require activation by KatG have tremendous
promise as novel drugs for combating MDR-TB and XDR-
TB (Rawat et al. 2003; Basso et al. 1998). Keeping in view,
the importance of enoyl-acyl carrier protein reductase
(InhA), an enzyme involved in the biosynthesis of mycolic
acids and low outcome of inhibitors using experimental
procedures, we have made an attempt to screen inhibitors
of InhA by virtual screening procedures.
Virtual screening (VS) is a widely used method that has
been shown to be successful in a variety of studies,
although it also has many shortcomings (Oprea and Matter
2004; Chen 2008). In the past few years, many reports
indicated that virtual screening techniques proved to be
effective in making qualitative predictions that discrimi-
nated active from inactive compounds (Kitchen et al.
2004). The use of experimentally derived protein structures
and a hybrid computational method that combines the
advantages of docking algorithms with dynamic structural
information provided by normal mode analysis certainly
provide improved library enrichments virtual screening
process. Furthermore, this is the first report of virtual
screening for InhA inhibitors and the results could aid




The native and mutant (I21V) type’s coordinates of INH-
NAD adduct complexed to InhA were taken from the
Brookhaven Protein Data Bank (PDB) (Berman et al.
2000). The corresponding PDB codes were 2IDZ and 2IE0,
respectively. The adduct was extracted from the PubChem,
a database maintained in NCBI (Wishart et al. 2008;
Feldman et al. 2006) and SMILES strings was collected
and submitted to CORINA for constructing the 3D struc-
ture of the INH-NAD adduct (Gasteiger et al. 1990). All
the water molecules and the hetero atoms were removed.
Energy minimization for native and mutant proteins was
carried out using GROMACS package 4.5.3 (Hess et al.
2008; Spoel et al. 2005) adopting the GROMOS43a1 force
field parameters before performing molecular docking
experiment. The screening performed with the aid of
PubChem and Drug bank database.
Virtual screening
VS (Shoichet 2004) is the computational analogue of bio-
logical screening. The approach has become increasingly
popular in the pharmaceutical research for lead identifica-
tion. The basic goal of the VS is the reduction of the
massive virtual chemical space of small organic molecules,
to screen against a specific target protein, to a manageable
number of the compounds that inhibit a highest chance to
lead to a drug candidate. Two different databases such as
PubChem and Drug bank were used for searching new lead
compounds by employing the INH-NAD adduct as query
(Bolton et al. 2011; Wishart et al. 2008). The numbers of
molecules in each of the database are 85 million and
140,000, respectively. Screening was carried out by
restricting the number of rotatable bonds to a maximum of
12 (Muegge 2003; Oprea 2000). Several hits were obtained
from each of the databases, which were further screened
using molecular docking studies. The SMILES strings were
used for constructing three-dimensional structures of lead
compounds.
Identification of binding site residues for enoyl-acyl
carrier protein reductase
It was a challenging task to extrapolate a mechanism of
action from the view of 3D structures. Detailed biochem-
ical information about the enzyme can be used to design
substrate or transition state analogues, which can then be
bound into the enzyme for structure determination. These
can reveal binding site locations and identify residues,
which are likely to take part in the receptor–ligand inter-
action. From this, a catalytic mechanism can be proposed.
In order to identify the binding residues in the structure of
enoyl-acyl carrier protein reductase, we submitted the
native and mutant complex structure (PDB ID: 2IDZ and
2IE0) into the ligand contact tool (LCT) program (Lopez
et al. 2007). This program calculates contacts between the
binding residues of enoyl-acyl carrier protein reductase
receptor with INHNAD using default parameters.
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Molecular docking
Docking was performed with the help of the PatchDock
(Duhovny et al. 2005). It is a geometry-based molecular
docking algorithm. The PatchDock algorithm divides the
Connolly dot surface representation (Connolly 1983a, b) of
the molecules into concave, convex and flat patches. Then,
complementary patches are matched in order to generate
candidate transformations. Each candidate transformation
is further evaluated by a scoring function that considers
both geometric fit and atomic desolvation energy (Zhang
et al. 1997). Finally, root mean square deviation (RMSD)
clustering is applied to the candidate solutions to discard
redundant solutions. The input parameters for the docking
are the PDB coordinate file of the protein and ligand
molecule. This algorithm has three major stages: (1)
molecular shape representation, (2) surface patch match-
ing, and (3) filtering and scoring. Furthermore, the steric
clashes, introduced by PatchDock, algorithm are removed
with the aid of FireDock algorithm (Andrusier et al. 2007;
Mashiach et al. 2008). FireDock refines side chain posi-
tions and relative protein orientations. After steric clashes
are removed, an energy-like function is used to rank the
docking models. This interface energy score is a weighted
combination of softened van der Waals, desolvation, elec-
trostatics, hydrogen bonding, disulfide bonding, p-stacking,
aliphatic interactions, and rotamer preferences (Andrusier
et al. 2007); docking results were screened by means of
FireDock algorithm.
Prediction of physiochemical properties
Successful drug discovery requires high-quality lead
structures which may need to be more drug-like than
commonly accepted (Proudfoot 2002). The hits were
screened using drug-likeness, drug score and toxicity
characteristics. These physicochemical properties were
therefore calculated for the filtered set of hits using the
program OSIRIS (Sander 2001). The OSIRIS program
calculates the drug-likeness based on a list of about 5,300
distinct sub-structure fragments created by 3,300 traded
drugs as well as 15,000 commercially available chemicals
yielding a complete list of all available fragments with
associated drug-likeness. The drug score combines drug-
likeness, cLogP, logS, molecular weight, and toxicity risks
as a total value which may be used to judge the com-
pound’s overall potential to qualify for a drug.
Normal mode analysis
The exploration of molecular motions of biological mole-
cules and their assemblies by simulation approaches such
as molecular dynamics has provided significant insights
into structure–function relationships in small biological
systems. Normal mode analysis (NMA) provides an alter-
native to molecular dynamics for studying the motions of
macromolecules. The time scale accessible to theoretical
work is extended with normal mode analysis, and this
approach has been proven extremely useful for studying
collective motions of biological systems. (Noguti and
Nishikawa 1983; Levitt et al. 1985) Normal mode analysis
is a powerful tool for predicting the possible movements of
a given macromolecule. It has been shown recently that
half of the known protein movements can be modeled by using
at most two low-frequency normal modes (Tama and Sane-
jouand 2001). Applications of NMA cover wide areas of
structural biology, such as the study of protein conformational
changes upon ligand binding, membrane channel opening and
closure, potential movements of the ribosome, and viral cap-
sid maturation. Another newly emerging field of NMA is
related to protein structure determination by X-ray crystal-
lography, where normal mode perturbed models are used as
templates for diffraction data phasing through molecular
replacement. Elnemo is a web interface to the elastic network
model that provides a fast and simple tool to compute, visu-
alize and analyze low-frequency normal modes of large
macro-molecules and to generate a large number of different
starting models for use in molecular replacement (Suhre and
Sanejouand 2004). Using this interface, each docked complex
was analyzed with default parameters to investigate the active
site residues by normal mode analysis.
Results and discussion
Virtual screening
Virtual screening is the computational analogue of bio-
logical screening. It uses computer-based methods to dis-
cover new ligands on the basis of biological structures.
This technique mainly focuses on comparing molecular
similarity analyses of compounds with known and
unknown moiety. Here, we have performed the virtual
screening analysis by using INH-NAD adduct, an active
intermediate molecule. The result indicates that 332 hits
from PubChem and 100 hits from Drug Bank were iden-
tified similar to the INH-NAD adduct. Successful drug
discovery requires high-quality lead structures which may
need to be more drug-like than is commonly accepted
(Proudfoot 2002). The initial screening was carried out by
restricting the number of rotatable bonds to a maximum of
12, which reduced the number of hits to 42 from drug bank
whereas PubChem database did not show the reasonable hit
compounds. The results are shown in Table 1. Therefore,
the subsequent analysis was carried out with the aid of 42
molecules screened from drug bank database.
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Binding site residues analysis
The binding site residues in the structure of enoyl-acyl
carrier protein reductase were obtained from LCT program
by using the complex structure of enoyl-acyl carrier protein
reductase bound with INH-NAD adduct (PDB ID: 2IE0).
The results indicate for 2IE0 are a total of 10 amino acid
residues, viz, G-14, S-20, V-21, D-64, V-65, I-95, G-96,
K-165, I-194 and T-196. The LIGPLOT (Wallace et al.
1995) tool was used to illustrate the contacts between
mutant protein binding residues and INH-NAD adduct
shown in Fig. 1.
Docking studies of mutant enoyl-acyl carrier protein
reductase with inhibitor
In order to gain insight into possible binding modes of the
inhibitor, INH-NAD adduct, was docked into the ligand-
binding domain of the native and mutant type of InhA
using the program PatchDock. It is well known that the
scores calculated by docking programs do not usually
permit the exact reproduction of the binding mode of
assayed compounds. Hence, we have further screened the
PatchDock results with the aid of FireDock program. This
will be of immense importance in obtaining the binding
affinity of INH-NAD adducts with the target structures.
The binding affinity between INH-NAD adducts and the
target structures determined by fireDock program were
-43.70 and -48.27 kcal/mol for the native and mutant
structures, respectively. This clearly indicates that mutation
at the position I21V in the target structure leads resistance
to drug molecule, isoniazid, but not to the INH-NAD
adduct. Subsequently, all 42 selected hits were docked into
the InhA active site in the same way in order to understand
the binding affinity of the lead compounds against the
native and mutant type proteins. We understand that 9 hits
showed greater binding affinity with the mutant type
(I21V) compared to INH-NAD adduct. The result was
shown in Table 2. In particular, five compounds such as
DB04362, DB03893, DB00157, DB02498 and DB04418
showed greater binding affinity with both native and
mutant type structure. The compound DB04362 showed
greatest binding affinity than other lead compounds con-
sidered in our study. The docked complex structure of
INH-NAD adduct and DB04362 with native and mutant
type structure shown in Figs. 2 and 3.
In silico toxicities, solubility, drug-likeness and drug
score profiles
Many drug candidates fail in the clinical trials, reasons are
unrelated in the potency against the intended drug target.
Table 1 Number of rotatable
bonds obtained from the
Molinspiration program
S. no. Compound ID Number of
rotatable bonds
S. no. Compound ID Number of
rotatable bonds
1 DB00157 11 22 DB01860 8
2 DB01907 11 23 DB03909 8
3 DB03797 11 24 DB02661 6
4 DB02498 11 25 DB04366 6
5 DB01893 9 26 DB04362 10
6 DB04497 11 27 DB02930 8
7 DB02059 9 28 DB03070 11
8 DB01842 8 29 DB01812 6
9 DB04099 11 30 DB03230 7
10 DB03431 6 31 DB02902 8
11 DB02363 8 32 DB02527 1
12 DB03363 11 33 DB03732 11
13 DB03969 11 34 DB00131 4
14 DB03478 11 35 DB04395 8
15 DB03020 11 36 DB02098 6
16 DB00171 8 37 DB02483 9
17 DB03893 11 38 DB03708 6
18 DB01660 8 39 DB04418 9
19 DB04554 6 40 DB03222 8
20 DB01774 9 41 DB02694 9
21 DB04071 11 42 DB07205 8
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Pharmacokinetic and toxicity issues are blamed for more
than half of all failure in the clinical trials. Therefore, it is
essential to evaluates Pharmacokinetic and toxicity of
small molecules. Drug solubility (log S) is an important
factor that affects the movement of a drug from the site of
administration into the blood. It is known that insufficient
solubility of drug can lead to poor absorption (Muegge
2003). Our estimated log S value is a unit stripped loga-
rithm (base 10) of a compound’s solubility measured in
mol/liter. There are more than 80 % of the drugs on the
market that have an (estimated) log S value greater than
-4. Table 3 shows solubility of the seven compounds that
were found in the comparable zone with that of standard
drugs to fulfill the requirements of solubility and could be
considered as a candidate drug for oral absorption.
Fig. 1 INH-NAD adduct bound with enoyl-acyl carrier protein reductase. The figure was rendered using the program LIGPLOT
Table 2 Binding free energy analysis of lead compounds






1 INH-NAD -43.70 -48.27
2 DB04362 -55.61 -57.27
3 DB02483 -38.69 -56.31
4 DB03893 -45.89 -54.34
5 DB04497 -24.28 -54.03
6 DB03732 -43.04 -53.45
7 DB03478 -38.92 -53.43
8 DB00157 -56.11 -53.35
9 DB02498 -46.73 -51.31
10 DB04418 -54.80 -50.58
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Drug-likeness
Currently, there are many approaches to assess a compound
drug-likeness based on topological descriptors, fingerprints
of molecular drug-likeness structure keys or other proper-
ties such as C log P and molecular weight. In this work,
Osiris program (Sander 2001) was used for calculating the
fragment-based drug-likeness of the most active com-
pounds and comparing them with INH-NAD adduct. Seven
compounds showed a little improvement of drug-likeness
values than INH-NAD adduct and it is shown in Table 3.
The drug scores of the potent compounds have also been
determined in the present study.
Drug score
We have calculated overall drug score (DS) for the lead
compounds as compared with that of standard drugs INH-
NAD adduct. The drug score combines drug-likeness, mi-
LogP, log S, molecular weight and toxicity risks in one
handy value that may be used to judge the compound’s
overall potential to qualify for a drug. The result is shown
in Table 3. The reported lead compounds showed moderate
to good drug score as compared with standard drug used.
The drug score of the seven compounds showed a good
score which is of significantly higher value than that of the
INH-NAD adduct.
The toxicity risk predictor locates fragments within a
molecule, which indicate a potential toxicity risk. Toxicity
risk alerts are an indication that the drawn structure may be
harmful concerning the risk category specified. Data
evaluated in Table 3 indicate that all the seven lead com-
pounds were supposed to be non-mutagenic, non-irritating
with no tumorigenic effects when run through the muta-
genicity assessment system comparable with standard
drugs used.
Normal mode docking analysis
It has been recently shown that half of the known protein
movements can be modeled by using at most too low-
frequency normal modes for explaining collective large
amplitude motions of proteins in different conformational
states (Delarue and Dumas 2004). These motions typically
Fig. 2 Docked complex of
INH-NAD adduct with native
(a) and mutant (b) type enoyl-
acyl carrier protein reductase
Fig. 3 Docked complex of
DB04362 with native (a) and
mutant (b) type enoyl-acyl
carrier protein reductase
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describe conformational changes which are essential for
the functioning of proteins (Alexandrov et al. 2005).
Hence, the lowest frequency mode (mode 7) (Choudhury
et al. 2010) was used for our docking study. The normal
mode analysis generates 11 possible confirmations between
DQMIN of -100 and DQMAX of 100 with DQSTEP step
size of 20 (Suhre and Sanejouand 2004). It is to be noted
that understanding the binding affinity between the target
and the drug based on relevant normal modes will autho-
rize the strength of docking process (Cavasotto et al. 2005).
Hence, entire trajectory files from the lowest frequency
mode were used as the input for docking analysis. Each
harmonic vibrational mode derived from NMA simulates a
state of the system in which all particles are oscillating
with the same characteristic frequency and, therefore, the
method is often referred to as collective motion analysis.
Unfortunately, the protein structure deposited in the PDB
corresponds to single conformation. Therefore, NMA,
particularly with a simple elastic network model, can be
helpful for simulation of an active site motion. The three-
dimensional structure of INH-NAD adduct was generated
by using the tool CORINA (Gasteiger et al. 1990). The
normal mode-based docking result is shown in Fig. 4. We
observed that free energy of binding for the lead com-
pound, DB04362, was significantly higher than INH-NAD
adduct in all the 11 conformations generated by means of
normal mode analysis. This clearly indicates the effective
binding of DB04362 than INH-NAD adduct with native
and mutant structure of InhA.
Conclusion
Despite the availability of effective treatments, tuberculo-
sis still persists as epidemiological entities that cause
chronic, crippling illness and death on a large scale. The
main reason for this is the emergence of drug-resistant
strains due to poor compliance among the patients to their
lengthy treatment regimens. Therefore, in the present
study, we identified novel drugs that are active against the
drug-resistant as well as non-resistant strains, and can
shorten their treatment durations using virtual screening
Table 3 Physicochemical
Properties of lead compounds
S. no. Compound Toxicity risks Osiris calculations
Mutagenic Tumorigenic Irritant Reproductive
effective
Log S DL DS
1 INH-NAD – – – – -5.75 -16.27 0.17
2 DB04362 – – – – -2.11 -12.8 0.3
3 DB02483 – – – – -3.1 -13.3 0.3
4 DB04497 – – – – -2.43 -15.54 0.28
5 DB03732 – – – – -2.44 -13.48 0.27
6 DB03478 – – – – -3.32 -15.52 0.29
7 DB00157 – – – – -4 -15.43 0.25
8 DB02498 – – – – -3.67 -13.78 0.25
Fig. 4 Comparison of free
energies of binding for the INH-
NAD adduct with native (black)
and mutant (red) structures
using normal mode analysis
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protocols. Initially, virtual compounds were subjected to
molinspiration program and screening was carried out by
restricting the number of rotatable bonds to a maximum of
12. Subsequently the screened molecules were docked at
the active site of Mtb InhA to select inhibitors establishing
favorable interactions. Finally, toxicity and drug-likeness
were evaluated in order to screen the high-quality lead
structure. Several potential drug-like inhibitors have been
screened out showing strong binding affinity to Mtb InhA.
Furthermore, normal mode analysis indicates that the
compound, adenosine diphosphate 5-(beta-ethyl)-4-methyl-
thiazole-2-carboxylic acid (DB04362) displayed strong
binding affinity with both the native and mutant type InhA.
Hence, we believed that DB04362 represents promising
starting point as a lead compound for Mtb. Though
experimental studies are indispensable to mark them as
lead compound for the development of novel drugs against
Mtb, however, screened out inhibitors would undoubtedly
aid the experimental designing of anti-tubercular agents
expeditiously.
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